Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Baxter missed earnings and sales forecasts, posted a larger loss, and cut 2026 outlook, spurring a 14.6% stock drop.

flag Baxter International reported fourth-quarter 2025 sales of $2.97 billion, up 8% year-over-year but only 3% on an operational basis, missing analyst expectations. flag Adjusted earnings per share were $0.44, below the $0.54 forecast, due to margin pressure, higher taxes, and a 900-basis-point drop in gross margin. flag The company posted a net loss of $1.12 billion, worsening from last year’s $512 million loss, with the Kidney Care segment now classified as discontinued. flag Despite growth in Advanced Surgery and Healthcare Systems, Pharmaceuticals and Injectables declined. flag Baxter issued weak 2026 guidance, projecting flat to 1% sales growth and adjusted EPS of $1.85–$2.05, below the market’s $2.25 estimate, causing its stock to fall 14.6% in pre-market trading.

4 Articles